LINCOLNSHIRE, Ill.--(Business Wire)--
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced its third quarter
2009 financial results.
BioSante incurred a net loss of approximately $6.4 million or ($0.21) per share
for the quarter ended September 30, 2009, compared to a net loss of $6.6 million
or ($0.24) per share for the same period in 2008. This decrease in net loss was
due to BioSante`s decision in April 2009 to delay screening of new subjects for
its ongoing LibiGel® (testosterone gel) Phase III safety study, partially offset
by the recognition of acquisition related costs of approximately $1.5 million
related to the Company`s merger with Cell Genesys Inc., which closed October 14,
2009. Screening of new subjects for the safety study has been reinitiated.
"There were three exciting and company-transforming events that occurred during
or shortly after the third quarter," said Stephen M. Simes, BioSante`s president
and CEO. "On August 13th, we closed a $12 million registered direct financing.
On October 14th, we closed our merger with Cell Genesys which together with the
$12 million financing gives us enough cash on hand to complete the LibiGel
clinical development program to and through submission of a new drug application
(NDA) in the first half of 2011. Finally, on October 20th we announced that the
independent Data Monitoring Committee (DMC) reviewed unblinded data in the
LibiGel Cardiovascular and Breast Cancer Safety Study and based on this review
of unblinded data, the DMC unanimously recommended continuation of the study as
described in the study protocol, with no modifications."
The Company`s cash and cash equivalents as of September 30, 2009 were
approximately $13.2 million, as compared to cash, cash equivalents and
short-term investments of approximately $14.8 million on December 31, 2008. As
of the completion of the merger with Cell Genesys on October 14, 2009, BioSante
gained $23.2 million in cash, cash equivalents and short-term investments, after
deducting anticipated estimated merger-related and other expenses, and assumed
$22.0 million in principal amount of 3.125% convertible senior notes issued by
Cell Genesys. In addition to the $23.2 million in cash, the Company obtained, as
a result of the merger, a portfolio of cancer immunotherapies (known as GVAX
Immunotherapies) and other technologies. Acquisition of these assets
significantly expands the Company`s product portfolio. Several GVAX
Immunotherapies now are in human clinical trials at the Johns Hopkins Sidney
Kimmel Comprehensive Cancer Center, at minimal cost to the Company.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products
for female sexual health, menopause, contraception and male hypogonadism.
BioSante`s lead products include LibiGel® (transdermal testosterone gel) in
Phase III clinical development by BioSante under a U.S. Food and Drug
Administration (FDA) SPA (Special Protocol Assessment) for the treatment of
female sexual dysfunction (FSD), and Elestrin (estradiol gel) developed through
FDA approval by BioSante, indicated for the treatment of moderate-to-severe
vasomotor symptoms associated with menopause, currently marketed in the U.S.
Also in development are Bio-T-Gel, a testosterone gel for male hypogonadism, and
an oral contraceptive in Phase II clinical development using BioSante patented
technology. The current market in the U.S. for estrogen and testosterone
products is approximately $2.5 billion and for oral contraceptives approximately
$3 billion. The company also is developing its calcium phosphate technology
(CaP) for aesthetic medicine (BioLook), as a vaccine adjuvant, including for an
H1N1 (swine flu) vaccine, and drug delivery. In addition, BioSante will seek
opportunities for its GVAX cancer immunotherapies and other newly acquired
technologies. Additional information is available online at:
www.biosantepharma.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking statements
often can be identified by words such as "will," "potential," "could," "can,"
"believe," "intends," "continue," "plans," "expects," "anticipates,"
"estimates," "may" or the negative of these words or other words of similar
meaning.Forward-looking statements by their nature address matters that are, to
different degrees, uncertain.Uncertainties and risks may cause BioSante`s actual
results to be materially different than those expressed in or implied by
BioSante`s forward-looking statements.For BioSante, particular uncertainties and
risks include, among others, the difficulty of developing pharmaceutical
products, obtaining regulatory and other approvals and achieving market
acceptance; the marketing success of BioSante`s licensees or sublicensees; the
success of clinical testing; BioSante`s need for and ability to obtain
additional financing; the effect of general business and economic conditions;
and risks arising from BioSante`s merger with Cell Genesys.More detailed
information on these and additional factors that could affect BioSante`s actual
results are described in BioSante`s filings with the Securities and Exchange
Commission, including its registration statement on Form S-4 filed in connection
with the merger with Cell Genesys and BioSante`s most recent annual report on
Form 10-K and subsequent quarterly reports on Form 10-Q.The information set
forth in this news release speaks only as of the date hereof, and BioSante
undertakes noobligation to update or revise any forward looking statement,
whether as a result of new information, future events or otherwise.
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
or
For information about participating in the LibiGel clinical studies call or
visit the following:
877-BLOOM81; www.bloomstudy.com
Copyright Business Wire 2009
